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Abstract  
Background: Of the 1.6 million South African people infected with human immunodeficiency virus (HIV), approximately 970,000 (55%) have 
been initiated on HAART. Despite these numbers, very little has been published about the safety profile of antiretroviral (ARV) medicines in the 
country. This study was performed at the Medunsa National Pharmacovigilance Centre and aimed to describe the demographic characteristics of 
patients enrolled in the pharmacovigilance surveillance study; highly active antiretroviral therapy (HAART) initiation regimen patterns; reasons for 
regimen changes; and adverse effects of ARV medicines. Methods: A cohort study of HIV-infected individuals aged 15 years or older who were on 
ARV medicines was conducted at four sentinel sites. Results: After HAART initiation, with an average lapse of 17.8 months (range: 0 – 83.8 
months), 2,815 patients were enrolled into the study. Results show that patients were observed for 1,606.2 person-years for pharmacy visits 
(collection of ARV medicines) and 817.1 person-years for clinical visits (consultation with the doctor). Females constituted 69.6% (1,958/2,815) of 
the study population. Almost all patients initiated HAART on first-line regimens (2,801/2,815). Some patients (6.7%, 190/2,815) dropped out of 
the study after HAART initiation. Reasons for regimen changes were not recorded for 2.5% (22/891) of the patients who changed regimens. The 
primary reason for regimen changes was drug-related toxicity (76.1%, 678/891), mostly evident in patients taking first-line regimens. Adverse 
effects  experienced  by  patients  were  polyneuropathy  (24.0%, 163/678);  lipodystrophy  (23.9%,  162/678);  neuropathy  (10.6%,  72/678);  and 
suspected lactic acidosis (3.8%, 26/678). Conclusion: The majority of prescribers complied with the HAART guidelines and initiated most patients 
on first-line regimens. However, adverse effects are evident in patients taking first-line regimens. We recommend that the Department of Health 
should  introduce  less  toxic  first-line  ARV  regimens.  Future  efforts  will  aim  to  initiate  patients  on  HAART  and  enrol  them  into  the  study 
simultaneously to determine early risk profiles of ARV medicines.  
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Background 
 
A majority of the 33 million people infected with the Human Immunodeficiency Virus (HIV) are in Sub-Saharan Africa [1]. According to South 
Africa’s mid-year population estimates for the year 2010, approximately 5.2 million of HIV-infected people reside in South Africa [2], of which one-
third need antiretroviral (ARV) medicines as their cluster of differentiation 4 (CD4) counts are below 350. Approximately 55% of South African 
residents who are in need of ARV medicines have been initiated on Highly Active Antiretroviral Therapy (HAART) since it was introduced into the 
country in the year 2003. Many others continue to seek treatment.  
  
Although ARV medicines have been extensively used and studied in developed countries with positive outcomes being reported, such as reduction 
in HIV-associated morbidity and mortality [3,4], this observation cannot be generalized to developing countries. Here, the incidence, patterns and 
severity of adverse reactions due to ARV medicines may differ markedly owing to local environmental and genetic influences. These influences may 
compromise the effectiveness of HAART programmes and lead to toxicity, intolerance, drug interactions, loss to follow-up and drug resistance 
amongst diverse populations such as that of South Africa. It has been found, for example, that some Acquired Immunodeficiency Syndrome (AIDS) 
restriction genes negatively influence HAART efficacy by delaying viral suppression and accelerating time to AIDS [5]. Therefore close monitoring 
of adverse drug reactions is paramount.  
  
Pharmacovigilance (PV), an activity concerned with the detection, assessment, understanding, management and prevention of adverse reactions to 
medicines [6], contributes to their safe and rational use. South Africa is one of the few developing countries in Africa with an existing PV system. 
The Medunsa National Pharmacovigilance Centre (MNPC), functional since the year 2007, is the only PV centre in South Africa using a structured 
surveillance system to assess and monitor the safety profile and impact of ARV medicines in adults and adolescents.  
  
When the roll-out of ARV medicines began in South Africa in 2003, the HAART initiation guidelines stated that all new patients needing HAART 
must initiate on first-line ARV regimens. First-line regimens are a combination of stavudine (d4T) or zidovudine (AZT); lamivudine (3TC); and 
efavirenz (EFZ) or nevirapine (NVP) [7]. Any form of resistance to these first-line regimens would require the patients to change to second-line 
ARV regimens. The financial and human implications of HIV drug resistance with first-line regimens are major. Second-line ARV regimens cost 
much more than first-line regimens [8]. Additionally, the development of drug resistance in a patient limits treatment options and increases the 
need for second-line regimens that maybe difficult to take [8]. Generally, second-line ARV drugs are bigger in size than first-line drugs (e.g. 
lopinavir/ritonavir) and therefore difficult to swallow. Some second-line drugs, such as indinavir, must be soaked in water before ingestion which 
makes the process of taking these ARV medicines awkward. In an attempt to broaden the options of first-line regimens,  the South African 
government has added tenofovir, emtricitabine and others in the new South African HAART guidelines (2010).  
  
Treatment-outcome data from a number of South African HAART programmes have been published. One such study is by Coetzee et. al. (2004) 
[9], published in the year 2004 when the scale-up of HAART roll-out had just begun in the South African public sector. This study aimed to 
promote  patient  adherence  to  ARV  medicines  [9].  The  HAART  programme  has  gradually  evolved  and  improved  since  then.  Another  study 
conducted in South Africa by Rosen et al. (2008) [10] explored demographic and socio-economic characteristics of patients enrolled in HAART 
programs in private and non-governmental organization clinics around the country but excluded public health care centres.  
  
Our study monitored patients enrolled in public sector health facilities, where the majority of HIV-infected patients in the country seek treatment. 
The purpose was to measure the demographic characteristics of these patients; determine their HAART initiation regimen patterns; determine 
reasons for regimen changes; and describe adverse effects experienced due to ARV medicines.  
  
  
Methods 
 
Study design, study population and study setting  
  
This cohort study included HIV-infected patients of 15 years of age or older who were receiving ARV medicines at selected sentinel sites in the 
South African public health sector. HIV-infected patients not taking ARV medicines were not eligible to participate in the study. The four sentinel 
sites were situated in three of South Africa’s provinces, namely Gauteng, Limpopo and Mpumalanga.  
  
Patient enrolment and data collection  
  
Onsite coordinators based at the sentinel sites used systematic random sampling to select HIV-infected patients visiting the health facilities. 
Patients who agreed to participate signed an informed consent form and were enrolled into the study. PV case report forms were completed by the 
onsite coordinator for every new patient at enrolment and for follow-up visits. Enrolled patients’ hospital records, laboratory reports, clinician’s 
notes and prescriptions were reviewed by the onsite coordinators. A retrospective data review of patient records was initially performed for the 
majority of patients to ascertain which regimen these patients initiated HAART on, as well as to obtain information on any regimens changes that 
had occurred prior to study enrolment of these patients. Thereafter, each time a study patient visited the health facility, they were interviewed by 
the onsite coordinator to identify and record any adverse effects the patient experienced while taking ARV medicines; as well to obtain information 
on regimen changes. All this information was recorded on the PV case report forms which were couriered to the MNPC and entered into an 
electronic database by data capturers based there.  
  
Definitions of reasons for changing or stopping regimens  
  
During patient interviews and record reviews, the following possible reasons for changing or stopping ARV regimens were identified:  
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1.  ARV-related toxicity, which includes adverse drug reactions (ADR) and side-effects. It is defined as the "manifestations of the adverse 
effects of drugs administered therapeutically or in the course of diagnostic techniques. It does not include accidental or intentional 
poisoning..." [11]. Such toxicity occurs at doses normally used in man and is directly linked to the presence of the drug. 2.  
 
2.  Dose-related toxicity occurs when increased dosages of (ARV or other) medicines are linked to increased adverse effects. When the dose 
is reduced, so is the frequency and severity of the adverse effects. This phenomenon appears with stavudine-containing regimens, for 
example, and is the rationale behind the call for lower stavudine content in the relevant regimens. For the purposes of this study, ARV-
related toxicity and dose-related toxicity have been distinguished as follows. ARV-related toxicity refers to an instance where one or 
more ARV drugs in a regimen have been changed due to adverse drug reactions. Dose-related toxicity refers to dose reductions to 
resolve the adverse event. A prime example is the reduction of the stavudine 40mg dose to 30mg, and even to 20mg, to limit the 
toxicities associated with it.  
 
3.  Treatment failure was defined as the cause for a decrease or increase in CD4 count or viral load respectively from the level it was at 
initiation into the study.  
 
4.  Guideline-related reasons for changes were those related to the South African HAART guidelines. For example, patients initiated on 
nevaripine are given 200mg doses once daily for two weeks before the dosage is  increased to  200mg twice daily thereafter. The 
regimen/guideline related reason was meant to account for such changes that are set out by the guideline.  
 
5.  TB treatment was defined as a patient taking concurrent TB treatment and HAART. Due to possible negative consequences of combining 
this treatment, a decision was made to stop HAART or to change to another regimen..  
 
6.  ARV non-availability was when the regimen that the patient had initially been taking was out of stock which resulted in a patient being 
changed to another regimen.  
 
7.  Poor  adherence  was  when  a  patient  was  not  adhering  to  the  prescribed  regimen.  This  was  both  self-reported  and  obtained  from 
pharmacy records. In the case of poor adherence, patients were usually counselled to improve adherence, after which treatment was to 
be re-started.  
 
8.  Patient decision was when treatment was stopped because a patient decided that s/he would discontinue HAART.  
 
9.  Pregnancy was when a patient fell pregnant whilst on a regimen containing a teratogen such as efavirenz.  
 
10.  Unknown was when a regimen had been changed but the reason for changing was not stated on the patient’s hospital records.  
  
Data management and analysis  
  
Data from PV case report forms were entered into a Structured Query Language database by data capturers. This data were extracted into an 
Excel 2007 document before being imported into Epi Info 3.5.1 (CDC) for validation. Both Epi Info 3.5.1 [12] and STATA TM version 11 (StataCorp 
® LP, College Station, TX, USA) [13] were used for data analysis. Univariate analyses were performed to describe various characteristics of the 
study population. Categorical data were described using frequencies and proportions. Normally distributed continuous data were described using 
frequencies  and  means,  while  medians  were  used  for  data  not  normally  distributed.  Statistical  significance  was  determined  using  the  95% 
confidence intervals.  
  
Ethical approval  
  
The project proposal which includes the work described in this paper was submitted to and approved by the Medunsa Research and Ethics 
Committee at the University of Limpopo in 2006 (Project number MP119/2006).  
  
  
Results 
 
A total of 2,835 patients was enrolled into this surveillance study since it began in January 2007 and until August 2011. Twenty of the 2,835 
patients did not meet the analysis criteria because they had pharmacy records missing, therefore, they were excluded from all analyses. Only 
2,815 patient data records were subsequently analysed. These patients were observed for 1,606.2 person-years for pharmacy visits (collection of 
ARV medicines) and 817.1 person-years for clinical visits (consultation with the doctor).  
  
Enrolment statistics  
  
Of the 2,815 patients, 930 (33.0%) were enrolled at Hospital A in Gauteng province; 511 (18.2%) at Hospital B in Mpumalanga province; the 
lowest number of patients (171, 6.1%) at Hospital D in Gauteng province and the greatest number of patients (1,203, 42.7%) at Hospital E in 
Limpopo province.  
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Gender and age  
  
The  overall  ratio  of  males  to  females  was 1:2.3  (Table  1).  The  most  frequent  age  of  male  and  female  patients  was 42  and 39  years  old 
respectively.  Patients’  ages  ranged  between  18  and 79. Patients  aged  less  than  25  years  at  HAART  initiation  comprised  5.1%  of  the  study 
population (Figure 1).  
  
HAART initiation and study enrolment  
  
The most common age group for HAART initiation amongst females was 30 – 34 years whilst that amongst males was bi-modal at 35 - 39 years 
and 40 – 44 years. In all provinces combined, 73.5% of HIV-infected patients initiated HAART at the age group 25 – 45 years old (Figure 1).  
  
A large number of patients (33.5%, 690/2,059) were enrolled into the PV surveillance study between four and nine months after HAART initiation 
(Figure 2). This calculation excluded all patients who initiated HAART before the MNPC was functional. Enrolment of patients into the study 
occurred at an average of 17.8 months after HAART initiation. Eight patients (0.4%) concurrently enrolled into the PV surveillance study the same 
day they initiated HAART. A longest interval observed between HAART initiation and study enrolment was 83.8 months. Patients who enrolled in 
the year 2007 had the shortest interval observed after HAART initiation.  
  
HAART initiation regimen patterns  
  
The recommended first-line regimens were prescribed to 99.5% (2,801/2,815) of patients. The ARV drugs included in these regimens are shown in 
Table 2. Of these patients, 2.8% (80/2,815) were initiated on the recently introduced tenofovir-containing first-line regimens (regimens A1 and 
A2). Eleven patients initiated HAART on non-standard regimens (0.4%, 11/2,815) whilst three patients (0.1%, 3/2,815) were initiated on second-
line regimens (Table 2).  
  
Regimen changes and stoppages  
  
The changes and stoppages focused on in this study were those that occurred in the period between HAART initiation and the first pharmacy visit 
after study enrolment.  
  
A total of 6.7% (190/2,815) patients did not return for their first pharmacy visit after study enrolment. These patients were classified as “drop-
outs”. When grouped by initiation regimens, the numbers of drop-outs observed in descending order were as follows: regimen 1c (10.2%, 12/118; 
non-standard regimens (9.1%, 1/11); regimen 1a (7.4%, 170/2,299); regimen A1 (2.7%, 2/73) and regimen 1b (1.8%, 5/285). Of the patients 
who returned for their first pharmacy visit after study enrolment, 1.5% (40/2,625) stopped HAART temporarily. As a result of patient drop-outs 
and regimen stoppages 2,585 patients remained active in our study. Of these, 34.5% (891/2,585) had their initiation regimens changed. This 
change occurred 14.9 months, on average, after HAART initiation (95% CI: 14.2 – 15.7). Figure 3 gives a clear summary of the regimen class 
changes that occurred amongst patients enrolled in the study.  
  
Amongst the patients that initiated HAART on first-line regimens, the majority of regimen changes (89.8%, 800/891) occurred within this regimen 
class (Figure 3). None of the patients who initiated HAART on non-standard regimens changed regimens on the first visit after study enrolment. 
One-third (33.3%, 1/3) of patients who initiated HAART on second-line regimens changed to first-line regimens.  
  
Reasons for regimen changes and stoppages  
  
Reasons for regimen changes are outlined in Table  3. Of the patients who changed initiation regimens due to ARV-related  toxicity, 76.1% 
(516/678) changed from regimen 1a to 1c. This number represents 22.4% of patients who commenced treatment on this regimen. Treatment 
failure was the second most common reason for regimen changes which was experienced mostly in patients who had initiated HAART on regimen 
1a (97.2%, 70/72). To put this in perspective, 70 of the 2,299 patients who initiated HAART on regimen 1a (3.0%) changed regimens for this 
reason. The reason for regimen changes was not recorded in 2.5% (22/891) of patients’ files and therefore was unknown.  
  
The four most common reasons given by the 40 patients (1.5%, 40/2,625) who temporarily stopped HAART were ARV-related toxicity (42.5%, 
17/40), poor adherence (30.0%, 12/40), non adherence (10.0%, 4/40) and patient decision (7.5%, 3/40).  
  
Adverse effects of ARV medicines  
  
Among the patients enrolled in this PV surveillance study, almost 50% (1,374/2,815) reported various medical conditions that could have been HIV 
and/or ARV-related. Conditions that were recorded as occurring  prior to initiation  of treatment were not counted as adverse effects of ARV 
medicines. The four most common adverse effects experienced by the 678 patients that changed ARV medicines due to ARV-related toxicity, were 
polyneuropathy (24.0%, 163/678), lipodystrophy (23.9%, 162/678), neuropathy (10.6%, 72/678), and suspected lactic acidosis (3.8%, 26/678). 
All  these  ARV-related  toxicities  were  experienced  by  patients  initiated  on  first-line  ARV  regimens  1a,  1b,  1c  and  A1.  Approximately  96.5% 
(654/678) of them were experienced by patients taking regimen 1a. In relation to the number of patients enrolled in the PV study, ARV-related 
toxicities of each regimen in descending order were as follows: regimen 1a (28.4%, 654/2,299); regimen 1c (13.6%, 16/118); regimen A1 (4.1%, 
3/73) and regimen 1b (1.8%, 5/285).  
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Discussion 
 
This is the first comprehensive report produced from the data collected at the MNPC. Very few patients enrolled into the PV surveillance study and 
initiated HAART simultaneously. Most patients had already been taking ARV medicines prior to study enrolment. Monitoring of adverse events 
associated with ARV medicines was therefore a challenge. The lowest number of enrolments was observed in Hospital D because this facility only 
began enrolling patients into the study in 2010. Hospital E, with the greatest number of patients enrolled is a large facility and had an onsite 
coordinator over the full period of the study.  
  
At  all  four  sentinel  sites,  the  same  demographic  pattern  was  observed  whereby  females  initiated  HAART  at  an  earlier  age  than  their  male 
counterparts. This is an indicator of gendered health seeking behavior. According to a study conducted by Skovdal et.al. (2011), males seek 
treatment at a later stage because they perceive themselves as physically strong and capable of withstanding disease. Additionally, they believe 
hospitals are places for women and children, not for men [14].  
  
The HIV gender imbalance, where more females than males are HIV-infected, is the norm for countries with a heterosexual population like South 
Africa, in which older men have sexual relationships with younger women, and men have more than one sexual partner at a time [15]. This is in 
stark contrast to the United States and Europe populations where more males are infected with HIV than females due to the higher prevalence of 
homosexuality in those countries.  
  
On examining the HIV population of the patients aged 25 years and less in this study, they seem to be under represented when compared to the 
same age group in a similar study in Cape Town [9]. However, this observation may support the Human Sciences Research Council (2008) data 
that HIV prevalence in the less than 25 year age group is declining in South Africa [16].  
  
The number of drop-outs in our study was not as high as has been observed in similar studies in South Africa [17,18]. A study by Dahab et al. 
(2008) in a South African public sector clinic revealed that 41% of patients voluntarily discontinued HAART or could not be found [19]. Reasons for 
patients being lost to follow-up were not assessed in our study.  
  
The prescribing practices of health care workers attending to patients enrolled in this study were found to be in accordance to the HAART initiation 
guidelines (the majority of patients were initiated on first-line ARV regimens). However, the World Health Organization’s (WHO) requirement that 
100% of HIV-infected patients must be initiated on first-line ARV regimens was not achieved.  
  
The four most frequently used initiation regimens in this surveillance study (regimens 1a, 1b, 1c and A1) differed from the four most frequently 
used regimens in a similar study in Cape Town (regimens 1a, 1c, 1d and non-standard regimens) [9]. This marked difference, where stavudine-
containing regimens (regimens 1a and 1b) predominated in this surveillance study in contrast to zidovudine-containing regimens (regimens 1c and 
1d) in the Cape Town study, may be due to the perception in the Cape Town cohort that treatment with stavudine is associated with peripheral 
neuropathy, a serious neurological complication of HIV disease. However, according to the WHO antiretroviral treatment guidelines (2007), as well 
as the South African HAART guidelines (2010), stavudine-associated peripheral neuropathy can be corrected by reducing the dosage of stavudine 
from 40mg twice daily to 30mg twice daily. Stavudine dosages as low as 20mg have been used in some patients enrolled in this PV surveillance 
study at Hospital A with no negative impact as yet. A study by Liddy (2009) [20] concluded that 20mg dosages of stavudine twice daily were not 
associated with loss of virological control and did not adversely affect CD4 count. However, due to the scarcity of available data regarding the use 
on the 20mg stavudine dosage, these results must be interpreted with caution.  
  
In resource limited settings such as South Africa, older and less expensive ARV medicines such as zidovudine and stavudine are still in use despite 
knowledge of their toxicity profiles. This is because very few options are available in such settings. Few patients were changed from first-line to 
second-line and non-standard regimens in our study. The WHO recommends that the complete regimen be changed from a first-line regimen to a 
second-line regimen in the case of treatment failure [21]. This guideline was mostly followed in our study population where necessary.  
  
ARV-related toxicity and treatment failure observed in our study were reported mostly in patients who initiated on regimens 1a and 1c. Although 
the frequency and the effects of drug-related toxicity have been assessed in clinical trials [22,23], they have not been sufficiently evaluated in 
clinical settings. Persistent adverse effects cause patients to be non-adherent resulting in the HI virus becoming resistant to treatment. This 
process ultimately results in treatment failure of that regimen. In the majority of patients who experience regimen 1a treatment failure, the options 
of regimens to which they will respond well are narrowed down, which poses a major challenge to the effective ongoing treatment.  
  
Many studies have reported the huge impact that adverse drug reactions have on health care in general and patients’ health in particular, but the 
actual scale of this burden cannot be accurately quantified because most cases are not reported and therefore go undetected. A study by Rajesh et 
al. (2010) [24] assessed the incidence of adverse drug reactions (ADRs) due to HAART in India and observed a higher incidence rate of ADRs in 
patients taking the zidovudine + lamivudine + nevirapine ARV drug combination than in any other ARV drug combination. This combination is 
equivalent to regimen 1d in our study. The results obtained in this Indian study [24] are in contrast to our study results where very few adverse 
effects were observed in patients taking regimen 1d. However, our results may be due to the limitation that there was a long interval between 
HAART initiation and study enrolment in the majority of patients. Such adverse effects may have been experienced by patients before they enrolled 
into our study and were therefore missed. Additionally, very few of our patients initiated on regimen 1d, which may have biased our results even 
further. Also, some reasons for regimen changes were not recorded in patient files, possibly leading to the underestimation of ADRs. Rajesh et al. 
(2010) [24] observed the lowest incidence rates of ADRs in patients taking the tenofovir + lamivudine + efavirenz ARV drug combination which is 
equivalent to regimen A1. Only lipodystrophy which is mostly common in patients taking stavudine-containing regimens was observed in one 
patient taking regimen A1 in our study. Despite this unusual observation, our results of low ADR incidence in patients taking regimen A1are 
consistent with those observed in the Indian study. The introduction of the new first-line regimens (regimens A1 and A2) has given health care Page number not for citation purposes  6 
workers  more  ARV  options  for  patients  to  prevent  drug-related  side  effects.  It  remains  very  important  to  prevent  regimen  changes  unless 
absolutely necessary.  
  
The results obtained in this study cannot be generalised to the rest of South Africa because data was only obtained from four sentinel sites located 
in three of South Africa’s nine provinces.  
  
 
  
Conclusion 
 
This PV study yields information applicable and relevant to the South African public health sector. Adverse effects of ARV medicines are evident in 
patients taking first-line ARV regimens. Future efforts will attempt to simultaneously initiate patients on HAART and enroll them into the study as 
well as to increase the number of sentinel sites to the rest of South Africa and include private health facilities. This step will help to obtain a 
complete profile for ADRs due to ARV medicines.  
  
Initiating more patients on tenofovir-containing regimens may reduce the scale of ARV-related toxicity. Our recommendations therefore are that 
the Department of Health must look into introducing more options of less toxic first-line ARV regimens into South Africa, Health care workers in the 
country should be sensitized to the importance of complete reporting of reasons for regimen changes and adverse effects experienced by patients 
taking ARV medicines to allow correct estimation of this burden. Further research will be conducted regarding the efficacy of the 20mg dosage of 
stavudine.  
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Table 1: Univariate analysis of characteristics of HIV-infected patients on HAART and enrolled in the PV surveillance study, 2007 
– 2011 
Demographic Information 
Males (n=856)  Females (n=1,959) 
  95% CI    95% CI 
Age in years (median)  44  43 – 45  39  39 – 40 
Age in years (*IQR)  38 – 51    34 – 47   
Age (in years ) at HAART initiation (median)  40  40 – 41  35  35 – 36 
Age (in years) at HAART initiation (IQR)  34. – 47    30– 42   
Gender (%)  29.8  28.1 – 31.5  70.2  68.5 – 72.9 
Populating group (%)         
Black  99.6  98.9 – 99.9  99.8  99.5 – 100 
Coloured  0.1  0.0 – 0.8  0.2  0.0 – 0.5 
White  0.2  0.0 – 1.0  0  0.0 – 0.0 
Indian  0  0.0 – 0.0  0  0.0 – 0.0 
*IQR (Interquartile range) 
  
  
 
 
 
Table 2: HAART initiation regimens prescribed to HIV-infected patients enrolled in the PV surveillance study, 2007 
– 2011 
HAART initiation regimens  N  %  95% CI 
First-line regimens    
     
d4T*  3TC*  EFZ*     (Regimen 1a)  2,299  81.7  80.2 - 83.1 
d4T  3TC  NVP*     (Regimen 1b)  285  10.1  9.1 - 11.4 
AZT*  3TC  EFZ     (Regimen 1c)  118  4.2  3.5 - 5.0 
AZT  3TC  NVP     (Regimen 1d)  19  0.7  0.4 - 1.1 
TDF*  3TC  EFZ  or FTC*  (Regimen A1)  73  2.6  2.1 - 3.3 
TDF  3TC  NVP     (Regimen A2)  7  0.3  0.1 - 0.5 
Total first-line regimens     2,801  99.5 
 
Second-line regimens    
 
   
AZT  ddl*  LPV/r*     (Regimen 2)  2  0.1  0.0 - 0.3 
TDF  3TC  LPV/r     (Regimen B1)  1  0.04  0.0 - 0.2 
Total second-line regimens     3  0.14 
 
Non-standard regimens    
     
Prescribers' combination     11  0.4  0.2 - 0.7 
Total initiation regimens     2,815  100 
 
*3TC – lamivudine; d4T – stavudine; EFZ – efavirenz; AZT – zidovudine; NVP – nevirapine; TDF – tenofovir; FTC – emictribane; 
 ddl – didanosine; LPV/r - lopinavir/ritonavir 
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Table 3: Reasons for changing HAART initiation regimens, 2007 – 2011 
Reasons for changing regimens  N  % 
Drug related toxicity  678  76.1 
Treatment failure  72  8.1 
Pregnancy  69  7.7 
Prescriber decision  19  2.1 
Other reasons*  31  3.5 
Not reported  22  2.5 
Total (N=2,815)  891  100 
*Non adherence, poor adherence, drug interaction, patient decision, ARV unavailability, guideline related 
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